Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity and Directorate Change

20 Nov 2019 07:00

RNS Number : 9687T
Tiziana Life Sciences PLC
20 November 2019
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 

Issue of equity and directorate change

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

New York/London, 20 November 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has issued 190,698 ordinary shares of 3p each ("Ordinary Shares") credited as fully paid at a price of 43p per share in satisfaction of a consultancy fee of £82,000. The Company also announces that Leopoldo Zambeletti has resigned as a director of the Company.

 

Issue of Equity

The Company has today issued 190,698 ordinary shares of 3p each ("Ordinary Shares") credited as fully paid at a price of 43p per share in satisfaction of a consultancy fee of £82,000.

Application will be made to the London Stock Exchange to admit the 190,698 new Ordinary Shares to trading on AIM. Admission of the new Ordinary Shares is expected to occur on or around 26 November 2019 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the issued share capital of the Company will be 136,654,516 Ordinary Shares and this figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest, the Company, under the Disclosure Guidance and Transparency Rules published by the UK Financial Conduct Authority. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

Directorate Change

The Company also announces that Leopoldo Zambeletti has tendered his resignation as a non-executive officer of the Company. The Company notes the significant business interests of Mr Zambeletti in a wide range of life sciences companies and expresses its gratitude for Mr Zambeletti's contribution to the Company during his tenure.

 

The person who arranged for release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

 

About Tiziana Life Sciences

 

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For further enquiries:

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379

 

Cairn Financial Advisers LLP (Nominated adviser) +44 (0)20 7213 0883

Liam Murray / Jo Turner

 

Shore Capital (Broker) +44 (0)20 7408 4050

Antonio Bossi / Fiona Conroy

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGGMWGUPBGMB
Date   Source Headline
9th May 200610:51 amRNSResearch Update
15th Mar 200611:01 amRNSFinal Results
14th Feb 20067:00 amRNSAcquisition
8th Feb 200611:00 amRNSAcquisition
9th Jan 200611:00 amRNSResearch Update
10th Oct 200510:51 amRNSEGM Statement
28th Sep 20059:07 amRNSResearch Update
22nd Sep 20054:26 pmRNSHolding(s) in Company
20th Sep 200512:26 pmRNSHolding(s) in Company
15th Sep 20058:05 amRNSIssue of Equity
15th Sep 20058:00 amRNSShare Finance Facility
15th Sep 20057:48 amRNSInterim Results
6th Sep 200510:27 amRNSAcquisition of Rights
10th Aug 200511:03 amRNSGrant of US Patent
18th Jul 200510:20 amRNSChange of Adviser
27th Jun 20057:00 amRNSResearch Update
20th Jun 20057:01 amRNSResearch Update
13th Jun 200512:59 pmRNSDirector Shareholding
26th Apr 20051:08 pmRNSResult of AGM
26th Apr 200512:39 pmRNSAGM Statement
15th Mar 20054:53 pmRNSStatement re ADR's
8th Mar 200511:15 amRNSDirectorate Change
4th Mar 20057:00 amRNSResearch Update
14th Feb 200512:19 pmRNSHolding(s) in Company
14th Feb 20057:00 amRNSResearch Update
9th Feb 20057:00 amRNSFinal Results
7th Feb 20054:50 pmRNSHolding(s) in Company
1st Feb 200512:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.